CN102895506A - 一种治疗慢性心力衰竭的中药颗粒胶囊 - Google Patents
一种治疗慢性心力衰竭的中药颗粒胶囊 Download PDFInfo
- Publication number
- CN102895506A CN102895506A CN2012103853346A CN201210385334A CN102895506A CN 102895506 A CN102895506 A CN 102895506A CN 2012103853346 A CN2012103853346 A CN 2012103853346A CN 201210385334 A CN201210385334 A CN 201210385334A CN 102895506 A CN102895506 A CN 102895506A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- traditional chinese
- cardiac failure
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002775 capsule Substances 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 206010019280 Heart failures Diseases 0.000 title abstract description 9
- 230000001684 chronic effect Effects 0.000 title abstract description 7
- 210000000582 semen Anatomy 0.000 claims abstract description 17
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 9
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 9
- 235000008434 ginseng Nutrition 0.000 claims abstract description 9
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 9
- 241000208340 Araliaceae Species 0.000 claims description 8
- 241000001350 Pterygiella tenuisecta Species 0.000 claims description 8
- 241000207929 Scutellaria Species 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 210000004072 lung Anatomy 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 6
- 230000007812 deficiency Effects 0.000 abstract description 5
- 210000003734 kidney Anatomy 0.000 abstract description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 3
- 230000035619 diuresis Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 238000010792 warming Methods 0.000 abstract description 3
- 208000006673 asthma Diseases 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 208000031971 Yin Deficiency Diseases 0.000 abstract 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 2
- 241000184350 Adonis aestivalis Species 0.000 abstract 1
- 206010011703 Cyanosis Diseases 0.000 abstract 1
- 244000257739 Dioscorea bulbifera Species 0.000 abstract 1
- 235000008532 Dioscorea bulbifera Nutrition 0.000 abstract 1
- 241000838335 Eremochloa ciliaris Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 206010019842 Hepatomegaly Diseases 0.000 abstract 1
- 206010030124 Oedema peripheral Diseases 0.000 abstract 1
- 241000953633 Ophiopogon latifolius Species 0.000 abstract 1
- 206010033557 Palpitations Diseases 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000019606 astringent taste Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 238000010926 purge Methods 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 11
- 230000000747 cardiac effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000004217 heart function Effects 0.000 description 5
- 238000012856 packing Methods 0.000 description 4
- 201000006306 Cor pulmonale Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 208000004124 rheumatic heart disease Diseases 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229960003883 furosemide Drugs 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000015210 hypertensive heart disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010002915 Aortic valve incompetence Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 201000002064 aortic valve insufficiency Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 description 1
- 208000030390 pulmonic stenosis Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种治疗慢性心力衰竭的中药颗粒胶囊，中医认为慢性心力衰竭病机中虚、瘀所致为多，气虚则鼓动气血无力；心阴亏耗，阴虚血涩；为此，本发明选择具有补心泻肺、和中温肾、强心利水的中药大叶沿阶草、草柏枝、福寿草、小黑药、肉桂、人参、五味子、麦冬、葶苈子、枳壳、甘草、黄芩，由我院制剂室制成胶囊，经多年临床试验，总有效率达到97.5％，心悸、气短、喘憋、发绀、下肢水肿、肝肿大等症状有了明显的改善，值得临床推广应用。
Description
技术领域
本发明涉及一种中药组合物，尤其涉及一种治疗慢性心力衰竭的中药颗粒胶囊
背景技术
慢性心力衰竭也称慢性充血性心力衰竭，是大多数心血管疾病的最终归宿，也是最主要的死亡原因。慢性心力衰竭指慢性原发性心肌病变和心室因长期压力或容量负荷过重，使心肌收缩力减弱，不能维持心排血量。分为左侧、右侧心力衰竭和全心衰竭。常见病因是风湿性心脏病、高血压、缺血性心脏病、心肌炎、主动脉瓣狭窄或关闭不全、室间隔缺损、肺原性心脏病、肺动脉瓣狭窄等。随着社会老年化的加剧和终末期心脏病患者数量的增多，慢性心力衰竭已成为我国的重大常见疾病之一。目前，仍以西药治疗为主，虽然短期内可控制症状，但常有反复发作。本院经过近几年的临床试验，认为中药治疗慢性心力衰竭具有疗效好，副作用小，可长期服用的优点。
发明内容
本发明的目的是提供一种治疗慢性心力衰竭的中药颗粒胶囊，慢性心力衰竭属于中医“胸痹”、“喘证”、“正忡”、“心悸”等范畴。病机中虚、瘀所致为多，气虚则鼓动气血无力；心阴亏耗，阴虚血涩；中医以补心泻肺、和中温肾、强心利水为治则。
本发明的目的是通过以下技术方案实现的，该治疗慢性心力衰竭的中药颗粒胶囊由以下重量份的中药制成：大叶沿阶草12-15份、草柏枝12-15份、福寿草12-15份、小黑药10-12份、肉桂8-10份、人参9-11份、五味子9-11份、麦冬9-11份、葶苈子11-13份、枳壳11-13份、甘草3-5份、黄芩11-13份。
优选的，大叶沿阶草13份、草柏枝13份、福寿草13份、小黑药11份、肉桂9份、人参10份、五味子10份、麦冬10份、葶苈子12份、枳壳12份、甘草4份、黄芩12份。
制备方法将以上所述中药，研成粉末，装入1号胶囊。
方中：大叶沿阶草安心安神，止咳化痰，治心悸；草柏枝养心安神，止血，治慢性心衰；福寿草强心利尿；小黑药补肺益肾；肉桂补火助阳，散寒止痛，温通经脉；人参大补元气，补脾益肺，生津安神；五味子敛肺滋肾，生津敛汗，涩精止泻，宁心安神；麦冬养阴润肺，益胃生津，清心除烦；葶苈子泻肺平喘，利水消肿；枳壳破气除痞，化痰消积；甘草：益气补中，清热解毒，祛痰止咳，缓解止痛；黄芩清热燥湿，泻火解毒，凉血止血。
临床资料
一般资料2006年5月-2009年5月我科收治慢性心力衰竭病人160例。心功能分级按纽约心脏病学会(NYHA)心功能分级标准，随机分为两组，治疗组80例，男50例，女30例；年龄35岁-75岁，平均年龄56岁，病程半年-5年，平均3年，原发病：冠心病20例，肺心病18例，高血压性心脏病15例，风湿性心脏病14例，扩张型心脏病13例；心功能：II级30例，III级24例，IV级26例；中医辨证分型参照《中医内科学》分为4型：心阳不振型16例，水气凌心型18例，气阴两虚型22例，瘀阻心脉型24例；对照组80例，男53例，女27例，年龄32岁-80岁，病程1年-6年；原发病：冠心病19例，肺心病21例；高血压性心脏病16例，风湿性心脏病13例，扩张型心肌病11例；心功能：II级29例，III级25例，IV级26例；两组年龄、性别、病程及病情比较无统计学意义(P＞0.05)，具有可比性。
诊断标准心力衰竭诊断参照《充血性心力衰竭学》；心功能分级参照美国心脏病协会标准委员会1997年修订的NYHA分级标准。
治疗方法治疗组服用以上所述中药颗粒胶囊，每日三次，每次5粒，对照组，口服地高辛(0.125-0.250)mg/d，利尿剂静脉注射呋塞米(速尿)(20-80)mg/d。两组均10天为一疗程。
疗效判定标准按NYHA标准判定：①显效：症状及体征消失，或心功能提高2级以上；②有效；症状及体征部分缓解或心功能改善1级；②无效：症状及体征无改善甚至加重或心功能改善不足1级。
治疗结果(1)两组治疗两个疗程后统计疗效见表一
表1两组治疗两周后疗效比较
从表1中可以看出，两组痊愈率、总有效率有显著性差异(P＜0.5)。
(2)两组治疗前后症状、体征比较见表2
表2两组治疗前后症状、体征比较
例
具体实施方式
实施例一：称取大叶沿阶草13g、草柏枝13g、福寿草13g、小黑药11g、肉桂9g、人参10g、五味子10g、麦冬10g、葶苈子12g、枳壳12g、甘草4g、黄芩12g，按将以上所述中药，研成粉末，装入1号胶囊。
实施例二：称取大叶沿阶草12g、草柏枝12g、福寿草12g、小黑药10g、肉桂8g、人参9g、五味子9g、麦冬9g、葶苈子11g、枳壳11g、甘草3g、黄芩11g，将以上所述中药，研成粉末，装入1号胶囊。
实施例三：称取大叶沿阶草15g、草柏枝15g、福寿草15g、小黑药12g、肉桂10g、人参11g、五味子11g、麦冬11g、葶苈子13g、枳壳13g、甘草5g、黄芩13g，将以上所述中药，研成粉末，装入1号胶囊。
Claims (2)
1.一种治疗慢性心力衰竭的中药颗粒胶囊，其特征在于该中药颗粒胶囊由以下重量份的中药制成：大叶沿阶草12-15份、草柏枝12-15份、福寿草12-15份、小黑药10-12份、肉桂8-10份、人参9-11份、五味子9-11份、麦冬9-11份、葶苈子11-13份、枳壳11-13份、甘草3-5份、黄芩11-13份。
2.根据权利要求1所述的一种治疗慢性心力衰竭的中药颗粒胶囊，其特征在于该中药颗粒胶囊由以下重量份的中药制成：大叶沿阶草13份、草柏枝13份、福寿草13份、小黑药11份、肉桂9份、人参10份、五味子10份、麦冬10份、葶苈子12份、枳壳12份、甘草4份、黄芩12份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210385334 CN102895506B (zh) | 2012-09-25 | 2012-09-25 | 一种治疗慢性心力衰竭的中药颗粒胶囊 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210385334 CN102895506B (zh) | 2012-09-25 | 2012-09-25 | 一种治疗慢性心力衰竭的中药颗粒胶囊 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102895506A true CN102895506A (zh) | 2013-01-30 |
| CN102895506B CN102895506B (zh) | 2013-12-18 |
Family
ID=47568192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210385334 Active CN102895506B (zh) | 2012-09-25 | 2012-09-25 | 一种治疗慢性心力衰竭的中药颗粒胶囊 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102895506B (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893350A (zh) * | 2014-04-01 | 2014-07-02 | 青岛市中心医院 | 一种用于治疗心力衰竭的中药及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (zh) * | 2001-01-14 | 2001-08-01 | 刘红 | 用于治疗充血性心力衰竭的药物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844C (zh) * | 2005-10-18 | 2007-03-21 | 北京格林富诚科技有限公司 | 二烷基－β－丙酸噻亭氢卤酸盐及羧酸盐的制备方法 |
-
2012
- 2012-09-25 CN CN 201210385334 patent/CN102895506B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1305844A (zh) * | 2001-01-14 | 2001-08-01 | 刘红 | 用于治疗充血性心力衰竭的药物 |
Non-Patent Citations (1)
| Title |
|---|
| 李雪梅，候晋生: "中医治疗心力衰竭的进展", 《甘肃中医学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103893350A (zh) * | 2014-04-01 | 2014-07-02 | 青岛市中心医院 | 一种用于治疗心力衰竭的中药及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102895506B (zh) | 2013-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108030864A (zh) | 一种治疗跌打损伤、烧伤及炎症的壮药药液 | |
| CN103316284A (zh) | 一种治疗胆结石的药物 | |
| CN102526611B (zh) | 一种治疗慢性心力衰竭的中药组合物 | |
| CN103893725A (zh) | 一种用于治疗脾肾阳虚型特发性水肿的中药 | |
| CN101209334B (zh) | 一种治疗肺癌的药物及其制备方法 | |
| CN102895506B (zh) | 一种治疗慢性心力衰竭的中药颗粒胶囊 | |
| CN102210839A (zh) | 一种治疗冠心病的中药胶囊 | |
| CN102579799B (zh) | 一种治疗产后血虚发热型的中药组合物 | |
| CN103860773A (zh) | 用于治疗心肌缺血的中药组合物及其制备方法 | |
| CN103893724A (zh) | 治疗妇女肝郁脾虚型特发性水肿的中药组合物 | |
| CN103285369B (zh) | 一种治疗心力衰竭的中药组合物 | |
| CN102935214B (zh) | 一种治疗尿毒症的中药组合物 | |
| CN105749216A (zh) | 一种治疗高血压的中药酒及其制备方法 | |
| CN105456924A (zh) | 含有艾叶的具有活血化瘀功能的中药制剂及其制备方法 | |
| CN103494939A (zh) | 一种治疗老年习惯性便秘的中药 | |
| CN107753866A (zh) | 一种治疗心衰症的中药组合物及其制备方法 | |
| CN107029098A (zh) | 一种中药制剂咳喘停胶囊 | |
| CN107281435A (zh) | 一种祛除人体湿气的祛湿汤颗粒及其制备方法 | |
| CN105727042A (zh) | 一种治疗肾炎水肿的中药汤剂 | |
| CN105288143A (zh) | 一种治疗哮喘的中药组合物 | |
| CN105688071A (zh) | 一种治疗间质性肺病的中药 | |
| CN105106599A (zh) | 一种用于治疗病毒性心肌炎的中药组合物及其制备方法 | |
| CN105381206A (zh) | 治疗脾虚胃弱型慢性胃炎的药物组合物及其制备方法 | |
| CN104825735A (zh) | 补肾保健药酒 | |
| CN103961603A (zh) | 一种降血脂通脉的中药制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: WANG SHAN Effective date: 20141231 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276300 LINYI, SHANDONG PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141231 Address after: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee after: Rudong science and Technology Center Address before: Department of medical affairs East Road, Yinan County Community Health Center 276300 Shandong Lake City of Linyi province Yinan County People Patentee before: Wang Shan |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20200414 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee before: Rudong science and Technology Center |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211112 Address after: 226400 Xinjian West Road, Fengli Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong Wenyuan Investment Development Co., Ltd Address before: 226400 No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong County Industrial and commercial information consulting service center |
|
| TR01 | Transfer of patent right |